75 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
, compared to $13.2 million for 2022. The increase was primarily related to higher employee compensation and benefits driven by increased headcount
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition … (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using
424B5
0sahrssls0hb u2l
13 Mar 24
Prospectus supplement for primary offering
4:04pm
424B5
v5le2an
11 Mar 24
Prospectus supplement for primary offering
4:06pm
424B4
8q3mcu yjsi0osxx
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-99.1
gegwf9 hc5edb6
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
ybn30f5w7 lb6tc609
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
bd6v0p 76icn1mcfp
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
4ghbwn6imi6j2o996l
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.2
m3f 7ps5wsgmdxre1q9v
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
zknzw mokn
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
v6dlknbhym7adnh
1 May 23
Departure of Directors or Certain Officers
7:30am